KYORIN Holdings, Inc.

Tokyo Stock Exchange 4569.T

KYORIN Holdings, Inc. EBITDA for the year ending March 31, 2024: USD 75.15 M

KYORIN Holdings, Inc. EBITDA is USD 75.15 M for the year ending March 31, 2024, a 11.41% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

KYORIN Holdings, Inc. EBITDA for the year ending March 31, 2023 was USD 67.45 M, a -5.82% change year over year.
KYORIN Holdings, Inc. EBITDA for the year ending March 31, 2022 was USD 71.62 M, a -15.07% change year over year.
KYORIN Holdings, Inc. EBITDA for the year ending March 31, 2021 was USD 84.33 M, a -15.33% change year over year.
KYORIN Holdings, Inc. EBITDA for the year ending March 31, 2020 was USD 99.60 M, a -7.20% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Tokyo Stock Exchange: 4569.T

KYORIN Holdings, Inc.

CEO	Mr. Yutaka Ogihara
IPO Date	Jan. 4, 2001
Location	Japan
Headquarters	6, Kanda Surugadai 4-Chome
Employees	2,042
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Tobacco

Description

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.

Key trends

Past 5 years